Cristina Gervasoni to Anti-HIV Agents
This is a "connection" page, showing publications Cristina Gervasoni has written about Anti-HIV Agents.
Connection Strength
1.807
-
Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic AIDS Rev. 2019; 21(1):40-49.
Score: 0.305
-
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
Score: 0.285
-
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
Score: 0.273
-
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
Score: 0.269
-
Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring. Antivir Ther. 2017; 22(4):361-363.
Score: 0.266
-
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
Score: 0.265
-
Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):193-201.
Score: 0.073
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.071